The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

Glaxosmithkline, with multiple operations in Montco, just scored a major regulatory win that could reshape how lupus nephritis is treated in children, ...

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March 2026, the company said in a notice to the state. The company said Monday ...

GlaxoSmithKline is plotting a $525M cost-cutting drive instead. GSK said in April it expects Advair's U.S. sales to drop 30% this year even without generics, ...

RELATED: GlaxoSmithKline and Vir finally score $1B supply deal for COVID antibody—6 months after FDA nod Continued emergence of omicron could spark a rush of sales for GSK-Vir's antibody therapy.

GlaxoSmithKline, maker of rosiglitazone (Avandia), hid negative trial results on the controversial diabetes drug more than a decade ago, according to a report released by the Senate Finance Committee.

Photo by Flickr user Ian Wilson Doctors will no longer be paid to speak on behalf of GlaxoSmithKline and its products, the British drug maker said Tuesday. In addition, the pharmaceutical company ...

Sydnie Mason laughs with her lab partner at the SNC GlaxoSmithKline Summer Immersion Experience in Biotech, a biotechnology ...

According to the company's Q4 press release, GlaxoSmithKline generated about $9.2 billion in sales, a 2% increase on a year-over-year basis, and delivered adjusted EPS of $0.27 per share.

Pharmaceutical comipany GlaxoSmithKline is under scrutiny following the death of children in Argentina. Parents believe that the experimental vaccines may be the cause of infant deaths.

GlaxoSmithKline and Sanofi-Synthélabo announced they've struck a deal for GSK to take fondaparinux and nadroparin in the event Sanofi's hostile bid for Aventis Pharmaceuticals--now under way--is ...